Analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.
Enzo Biochem Price Performance
NYSE:ENZ opened at $0.48 on Tuesday. Enzo Biochem has a one year low of $0.41 and a one year high of $1.40. The company’s 50-day simple moving average is $0.72 and its 200 day simple moving average is $0.97.
Enzo Biochem (NYSE:ENZ – Get Free Report) last posted its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.
Institutional Trading of Enzo Biochem
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
See Also
- Five stocks we like better than Enzo Biochem
- How to Calculate Inflation Rate
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- What is diluted earnings per share (Diluted EPS)?
- Inflation Persists, But So Do Stock Opportunities: Rally On
- What Makes a Stock a Good Dividend Stock?
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.